GlassScriptPhysician profile
Syed S Mahmood
NPI 1942521216
$5,561.69
in general payments reported to CMS, 2019-2025
25 companies · $1,052 in 2025
The $1,052 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $3,076 · 2021: $205 · 2022: $363 · 2023: $108 · 2024: $507 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,354 · Travel and Lodging: $295 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,354.19 |
| Travel and Lodging | $295.24 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $2,472.39 | 2020-2025 | Xtandi, Vyloy |
| Astrazeneca Pharmaceuticals LP | $896.42 | 2019-2025 | Imfinzi, Calquence |
| Intuitive Surgical, INC. | $295.24 | 2025 | |
| Novartis Pharmaceuticals Corporation | $250.51 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $216.56 | 2022-2024 | Ultomiris |
| Pfizer INC. | $211.87 | 2024-2025 | |
| Abbvie INC. | $161.33 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $108.24 | 2024-2025 | Keytruda |
| Celgene Corporation | $108.14 | 2021-2024 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $100.58 | 2021-2024 | Akeega, Erleada |
| Tempus Ai, INC | $92.18 | 2025 | Xt Cdx |
| Foundation Medicine, INC. | $87.45 | 2019-2020 | |
| Beigene USA, INC. | $85.88 | 2021-2025 | Brukinsa, Tevimbra |
| Karyopharm Therapeutics INC. | $79.53 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $65.55 | 2024-2025 | Opdivo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $60.44 | 2021-2024 | |
| Daiichi Sankyo INC. | $56.12 | 2023-2025 | Enhertu, Injectafer |
| Eisai INC. | $49.16 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $40.92 | 2025 | |
| Glaxosmithkline, LLC. | $31.94 | 2025 | Jemperli, Zejula |
| Beone Medicines USA, INC. | $23.23 | 2025 | Brukinsa |
| Incyte Corporation | $19.55 | 2023 | Monjuvi |
| Seagen INC. | $19.24 | 2023 | Tukysa |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2025 | Libtayo |
| Fortovia Therapeutics, INC. | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Mahmood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.